<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03261999</url>
  </required_header>
  <id_info>
    <org_study_id>FP01C-17-001</org_study_id>
    <secondary_id>2017-001333-88</secondary_id>
    <nct_id>NCT03261999</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer</brief_title>
  <official_title>An Open-Label, Single-Arm Study of The Efficacy, Safety, and Pharmacokinetic Behavior of Leuprolide Mesylate Injectable Suspension (LMIS 25 mg) in Subjects With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foresee Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Foresee Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of
      subjects with prostate cancer, when administered as two injections twelve weeks apart.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-national, multi-center, open-label, single-arm study. All subjects will be
      males with prostate cancer judged to be candidates for medical androgen ablation therapy and
      all will receive two injections of LMIS 25 mg twelve-week apart in an unblinded fashion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Leuprolide Mesylate (LMIS 25mg)</measure>
    <time_frame>168 days</time_frame>
    <description>The percentage of subjects with a serum testosterone concentration suppressed to castrate levels (≤ 50 ng/dL) from Day 28 through Day 168.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-suppression excursions of serum testosterone</measure>
    <time_frame>168 days</time_frame>
    <description>The proportion of subjects exhibiting post-suppression excursions of serum testosterone to &gt;50 ng/dL through the &quot;acute-on-chronic&quot; phenomenon (i.e., related to the second dose of LMIS 25 mg); Effect of LMIS 25 mg on serum PSA levels; and Effect of LMIS 25 mg on serum LH levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Leuprolide Mesylate (LMIS 25mg)</measure>
    <time_frame>Days 0, 1, 2, 3, 7, 14, 21, 28, 42, 56, 77, 84, 85, 86, 87, 98, 112, 126, 140, 161, 168, 182</time_frame>
    <description>Plasma leuprolide concentrations (ng/mL) in PK population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of injection site reaction</measure>
    <time_frame>0, 1, 2, 84, 85, 86 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone pain measurement (by Visual Analogue Scale [VAS] scale)</measure>
    <time_frame>0, 1, 7, 14, 28, 56, 84, 112, 140, 168 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary signs and symptoms and total scores assessed by the International Prostate Symptom Score (I-PSS) sheet</measure>
    <time_frame>168 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in 12-lead resting electrocardiogram (ECG) per the investigator's judgment</measure>
    <time_frame>0, 28, 84, 168 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vital signs (BP, HR, RR, weight)</measure>
    <time_frame>0 - 168 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lab data</measure>
    <time_frame>0 - 168 days</time_frame>
    <description>Including liver function (AST, ALT, ALP), renal function (BUN, SCr), complete blood count with platelets, clinical chemistries (K, Na, Mg, Ca and P), urinalysis, serum glucose, lipid profile (LDL, HDL, triglycerides) and HbA1c level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subject achieving normal serum PSA level (&lt;4 ng/dL)</measure>
    <time_frame>Day 168 (week 24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with serum testosterone concentration suppression to ≤ 20 ng/dL</measure>
    <time_frame>Day 28 (week 4) and Day 168 (week 24)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">133</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Leuprolide Mesylate 25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be males with prostate cancer. They will be injected twice with a depot formulation containing 25 mg of Leuprolide Mesylate.
The first dose on day 0 and the second dose on day 84 (twelve weeks apart). Subjects will be followed until day 168.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Mesylate</intervention_name>
    <description>Subcutaneous injection of 25mg Leuprolide Mesylate</description>
    <arm_group_label>Leuprolide Mesylate 25mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males aged ≥ 18 years old

          2. Males with histologically confirmed carcinoma of the prostate

          3. Subjects who are judged by the attending physician and/or Principal Investigator to be
             a candidate for androgen ablation therapy

          4. Baseline morning serum testosterone level &gt; 150 ng/dL performed at Screening Visit

          5. Eastern Cooperative Oncology Group (ECOG) Performance score ≤ 2

          6. Life expectancy of at least 18 months

          7. Laboratory values

               -  Absolute neutrophil count ≥ 1,500 cells/µL

               -  Platelets ≥ 100,000 cells/µL

               -  Hemoglobin ≥ 10 gm/dL

               -  Total bilirubin ≤ 1.5 × upper limit of normal (ULN)

               -  AST (SGOT) ≤ 2.5 × ULN

               -  ALT (SGPT) ≤ 2.5 × ULN

               -  Serum creatinine ≤ 1.5 mg/dL

               -  Lipid profile within acceptable range according to investigator's opinion

               -  Serum glucose within acceptable range according to investigator's opinion

               -  HgbA1c within acceptable range according to investigator's opinion

               -  Clinical chemistries (K, Na, Mg, Ca and P) within acceptable range according to
                  investigator's judgment

               -  Serum glucose within acceptable range according to investigator's judgement

               -  Urinalysis within normal range according to the investigator's judgment

          8. Agree to use male contraceptive methods during study trial

          9. Based on the Investigator's judgment, the ability to understand the nature of the
             study and any hazards of participation, and to communicate satisfactorily with the
             Investigator and to participate in, and to comply with, the requirements of the entire
             protocol

         10. All aspects of the protocol explained and written informed consent obtained

        Exclusion Criteria:

          1. Receipt of chemotherapy, immunotherapy, cryotherapy, radiotherapy, or anti- androgen
             therapy concomitantly, or within 8 weeks prior to Screening Visit, for treatment of
             carcinoma of the prostate. Radiation for pain control will be allowed during the
             study.

          2. Receipt of any vaccination (including influenza) within 4 weeks of screening visit

          3. History of blood donation within 2 months of screening visit

          4. History of anaphylaxis to any LH-RH analogues

          5. Receipt of any LHRH suppressive therapy within 6 months of screening visit

          6. Major surgery, including any prostatic surgery, within 4 weeks of screening visit

          7. History and concomitant clinical and radiographic evidence of central nervous
             system/spinal cord metastases and subjects at risk for spinal cord compression

          8. Clinical evidence of active urinary tract obstruction and subjects at risk for urinary
             obstruction

          9. History of bilateral orchiectomy, adrenalectomy, or hypophysectomy

         10. History or presence of hypogonadism, or receipt of exogenous testosterone
             supplementation within 6 months of Baseline

         11. Clinically significant abnormal ECG and/or history of clinically significant
             cardiovascular disease as judged by the investigator

         12. History of drug and/or alcohol abuse within 6 months of Baseline

         13. Contraindication to leuprolide or an LHRH agonist as indicated on package labeling

         14. Use of 5-alpha reductase inhibitor within the last 6 months of screening visit

         15. History or presence of insulin-dependent diabetes mellitus (Type I). Presence of well
             controlled diabetes mellitus Type II will be allowed if only oral hypoglycemic are
             required. Prostate cancer subjects with poor controlled diabetes mellitus with Hb1Ac &gt;
             9.5% or urine glycosuria &gt; 1.0 g/dL should be excluded.

         16. Use of systemic corticosteroids at a dose &gt;10 mg/d or anti-androgens

         17. Use of any investigational agent within 4 weeks of screening visit

         18. Use of any over-the-counter (OTC) medication within 4 weeks of screening visit except
             for those listed in the permitted Concomitant Treatment section.

         19. Uncontrolled intercurrent illness that would jeopardize the subject's safety,
             interfere with the objectives of the protocol, or limit the subject's compliance with
             study requirements, as determined by the Investigator in consultation with the Sponsor
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Mao, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Foresee Pharmaceuticals Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Mao, PhD</last_name>
    <phone>+1 650-421-1016</phone>
    <email>john.mao@foreseepharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yen-Ling Lin, PhD</last_name>
    <phone>+886 2-2655-2658</phone>
    <phone_ext>7309</phone_ext>
    <email>yenling.lin@foreseepharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Urology Centers of Alabama</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Morgan</last_name>
      <email>smorgan@urologyal.com</email>
    </contact>
    <contact_backup>
      <last_name>Tosha Pringle</last_name>
      <email>tpringle@urologyal.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mark DeGuenther, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Institute of Urology</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Belkoff, DO</last_name>
      <email>kbelkoff@aiurology.com</email>
    </contact>
    <contact_backup>
      <last_name>Marcie Tarlton</last_name>
      <phone>855-382-7804</phone>
      <email>mtarlton@aiurology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kenneth Belkoff, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Urology Center of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lawrence Karsh, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Clinical Trials, LLC</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio, P.A</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Ramirez</last_name>
      <email>Laura.Ramirez@urologysa.com</email>
    </contact>
    <contact_backup>
      <last_name>Manuel Hernandez</last_name>
      <email>manuel.hernandez@urologysa.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Talley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia, PLLC</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jack Lambert, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Hradec Králové, Urologická klinika</name>
      <address>
        <city>Hradec Králové</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Miloš Broďák, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uromedical Center Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vladimir Študent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomayerova nemocnice, Urologické oddělení</name>
      <address>
        <city>Praha</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roman Zachoval, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inyoung Jeong</last_name>
      <email>iyjeong@pnuh.co.kr</email>
    </contact>
    <investigator>
      <last_name>Hong Koo Ha, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seo Hyeon Jeong</last_name>
      <email>sorceress_11@naver.com</email>
    </contact>
    <investigator>
      <last_name>Chun-il Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jung Eun Kim</last_name>
      <email>kje0917@ncc.re.kr</email>
    </contact>
    <investigator>
      <last_name>Jae Young Joung, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hosptal</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sung Kyu Hong, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong-Ju Lee</last_name>
      <email>apple730729@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Jin Seon Cho, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji-Hyun Lee</last_name>
      <email>tudwnlsss@naver.com</email>
    </contact>
    <investigator>
      <last_name>Seok-ho Kang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kauno klinikos</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mindaugas Jievaltas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klaipėda University Hospital</name>
      <address>
        <city>Klaipėda</city>
        <zip>92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Raimundas Venckus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Vilnius</city>
        <zip>08660</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Feliksas Jankevičius, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital, Santaros klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Henrikas Ramonas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UROCENTRUM MILAB, s.r.o.</name>
      <address>
        <city>Prešov</city>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ivan Minčík, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultná nemocnica s poliklinikou Žilina Urológia</name>
      <address>
        <city>Žilina</city>
        <zip>012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juraj Mikuláš, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2017</study_first_submitted>
  <study_first_submitted_qc>August 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2017</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Neoplasm Cancer Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

